Bonus Biogroup

Bonus Biogroup Equity

The The Equity of Bonus Biogroup (BONS.TA) as of Oct 30, 2026 is -5.66 M ILS. In the previous year, The Equity was 6.96 M ILS — a change of -181.41% (lower).

Equity

-5.66 MILS

YoY

-181.41%

Last updated:

In 2025, Bonus Biogroup's equity was -5.66 M ILS, a -181.41% increase from the 6.96 M ILS equity in the previous year.

The Bonus Biogroup Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
-31,770.00 ILS
Jan 1, 2019
-137,210.00 ILS
Jan 1, 2020
306,840.00 ILS
Jan 1, 2021
844,300.00 ILS
Jan 1, 2022
563,890.00 ILS
Jan 1, 2023
29.31 M ILS
Jan 1, 2024
6.96 M ILS
Jan 1, 2025
-5.66 M ILS
The Bonus Biogroup Equity history
YEAREquityYoY
-5.66 MILS-181.41%
6.96 MILS-76.26%
29.31 MILS+5,096.94%
563,890.00ILS-33.21%
844,300.00ILS+175.16%
306,840.00ILS-323.63%
-137,210.00ILS+331.89%
-31,770.00ILS-50.23%
-63,840.00ILS-99.13%
-7.36 MILS+430.09%
-1.39 MILS-329.97%
604,000.00ILS—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bonus Biogroup Stock analysis

What does Bonus Biogroup do? The Bonus Biogroup Ltd is a biotechnology company based in Israel that specializes in the development and marketing of innovative medical products and therapies based on human bone marrow stem cells. The company was founded in 2008 by a group of scientists, doctors, and entrepreneurs who came together to explore and develop new approaches in regenerative medicine. The business model of Bonus Biogroup is based on utilizing the benefits of stem cells for tissue and organ regeneration. Mesenchymal stem cells (MSC), derived from bone marrow, play an important role in this process. These stem cells have the ability to differentiate into various cell types and have anti-inflammatory properties. Bonus Biogroup aims to utilize MSC technology for the development of innovative medical products and therapies to help patients with serious diseases. The company is divided into several business areas, each offering its own products and services. A key area is the development of implants and other medical devices coated with bone marrow stem cells. These products are intended to promote tissue regeneration in the body, particularly in the treatment of bone and cartilage defects and joint diseases. An example is the BioGrip implant, used in patients with osteoporosis to prevent or reduce bone fractures. Another business area of Bonus Biogroup is the production and marketing of cell therapies. In this process, mesenchymal stem cells are obtained from the patient's bone marrow and processed in a special procedure. The stem cells are then directly injected into the affected area to promote tissue regeneration. These cell therapies are used in patients with rheumatism, arthritis, joint pain, or spinal problems. In addition to research and development of new products and therapies, Bonus Biogroup also operates a large stem cell bank. This bank collects and stores human bone marrow from donors for later use in the production of implants and cell therapies. The stem cell bank is a crucial part of the business model, as it ensures a consistent and high-quality supply of mesenchymal stem cells. In summary, Bonus Biogroup is an innovative biotechnology company specializing in the use of human bone marrow stem cells. The business model is based on the development and marketing of implants, cell therapies, and other medical devices to promote tissue regeneration in the body. The company also operates a large stem cell bank to ensure a consistent supply of high-quality mesenchymal stem cells. The company has the potential to become a significant player in regenerative medicine, making a valuable contribution to improving the health and quality of life of patients. Bonus Biogroup is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Bonus Biogroup's Equity

Bonus Biogroup's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Bonus Biogroup's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Bonus Biogroup's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Bonus Biogroup's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Bonus Biogroup’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Bonus Biogroup stock

The Equity of Bonus Biogroup is -5.66 M ILS in 2025.

The Equity of Bonus Biogroup changed from 6.96 M ILS to -5.66 M ILS, representing a -181.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Bonus Biogroup since 2006 – with annual values, charts, and detailed analysis.

The Equity's ILS is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Bonus Biogroup historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Bonus Biogroup

All Key Metrics — Bonus Biogroup